Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Kg

Boehringer Ingelheim Pharma Gbmh Co. Kg

Christel Schmelzer

Birgit Jung

Richard Reichl

Michael Paul Pieper

Hubert Hoelz

Michel Pairet

Christopher John Montague Meade

Hans-Hermann Weil

Friedrich Schmidt

Franz-Rainer Weitzel

Mariola Mann

Arne Froemder

Karin Drechsel

Barbara Niklaus-Humke

Petra Barth

The present invention relates to propellant-free aerosol formulations for inhalation containing ipratropium bromide and salbutamol.

Propellant-free aerosol formulation for inhalation

The invention relates to pressurized gas formulations for dosage aerosols, in which a medicament is formulated suspended in TG 227 ea (1,1,1,2,3,3,3-heptafluoropropane) and/or TG 134 a (1,1,1,2-tetrafluoroethane) as a propellant, and to their use for producing a medicament. The aerosol is preferably an inhalation aerosol.

Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant

Disclosed are propellant gas formulations containing at least one suspended active substance which contains chemically bound water, water and the propellant TG 227 or TG 134 a.

Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant

A pharmaceutical composition comprising an anticholinergic and at least one additional active ingredient selected from among corticosteroids, dopamine agonistes, PDE-IV inhibitors, NK1-antagonists, endothelin antagonists, antihistamines, and EGFR-kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.

Pharmaceutical compositions based on anticholinergics and additional active ingredients

The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1&#x3b1;,2&#x3b2;,4&#x3b2;,5&#x3b1;,7&#x3b2;)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0]nonane-bromide.

HFA supension formulations containing an anticholinergic

HFA suspension formulations containing an anticholinergic

The invention relates to propellant gas formulations containing suspensions of the crystalline anhydrate of (1&#x3b1;,2&#x3b2;,4&#x3b2;,5&#x3b1;,7&#x3b2;)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0]nonane-bromide.

HFA suspension formulations of an anhydrate

A liquid, propellant-free pharmaceutical preparation comprising:

Growing community of inventors

Ingelheim am Rhein, Germany

Christel Schmelzer